Skip to content

Hospital centralized monitoring of clinical safety of Shenkang Injection after marketing

Hospital centralized monitoring of clinical safety of Shenkang Injection after marketing

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2100005034
Enrollment
Unknown
Registered
2021-07-06
Start date
2021-08-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Sponsors

The First Affiliated Hospital of He'nan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: During the monitoring period, inpatients receiving Shenkang injection treatment in each monitoring hospital.

Exclusion criteria

Exclusion criteria: Inpatients who are unable to collect the information needed for this study.

Design outcomes

Primary

MeasureTime frame
Adverse Drug Reactions/Events;

Countries

China

Contacts

Public ContactLi Xuelin

The First Affiliated Hospital of He'nan University of Chinese Medicine

lixuelin450000@163.com+86 13703711133

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026